C4 Therapeutics

C4 Therapeutics is an American biotechnology company. It focuses on novel early stage therapies that eliminate disease-causing proteins for the treatment of cancer, neurological, and other diseases. C4 Therapeutics serves customers in the State of Massachusetts.
C4 Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

C4 Therapeutics balance sheet

Report period2018 2019 2020 2021 2022Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

C4 Therapeutics cash flows

Report period2018 2019 2020 2021 2022Q2 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

C4 Therapeutics multipliers

Report period2018 2019 2020 2021 2022Q2 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

C4 Therapeutics profitability

Report period2018 2019 2020 2021 2022Q2 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
C4 Therapeutics assets
C4 Therapeutics cash flows

C4 Therapeutics dividend policy

The company doesn't provide dividend

C4 Therapeutics shares

TickerNameTypeNominal valueISINPrice
CCCC:USC4 TherapeuticsCommon share-US12529R1077$6.64
C4 Therapeutics news
05.05.2022
C4 Therapeutics' GAAP loss for 3 months of 2022 was $31.62 million, up 50.8% from $20.971 million in the prior year. Revenue increased 3.1% to $7.654 million from $7.426 million a year earlier.
Source: {source} pictogram ir.c4therapeutics.com
Pictogram next
24.02.2022
C4 Therapeutics' GAAP loss for 2021 was $83.892 million, up 26.5% from $66.335 million in the prior year. Revenue increased 37.9% to $45.785 million from $33.195 million a year earlier.
Source: {source} pictogram ir.c4therapeutics.com
Pictogram next
11.11.2021
C4 Therapeutics' GAAP loss for 9M 2021 was $68.234 million, up 53.2% from $44.54 million in the prior year. Revenue increased 3.1% to $25.707 million from $24.933 million a year earlier.
Source: {source} pictogram ir.c4therapeutics.com
Pictogram next
12.08.2021
FDA has granted candidate CFT7455 from C4 Therapeutics orphan drug status. CFT7455 is being developed to treat multiple myeloma. The drug could also be used to treat non-Hodgkin's lymphoma, including peripheral T-cell lymphoma and mantle cell lymphoma. In June, the company initiated a phase 1/2 clinical trial in which it plans to enroll 160 participants.
Source: {source} pictogram ir.c4therapeutics.com
Pictogram next
All C4 Therapeutics news
General information
Company nameC4 Therapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address490 Arsenal Way Suite 200 Watertown, MA 02472 United States
Websiteir.c4therapeutics.com
Information disclosurewww.sec.gov